Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

dc.creatorKatlama, Christine
dc.creatorClotet, Bonaventura
dc.creatorMills, Anthony
dc.creatorTrottier, Benoit
dc.creatorMolina, Jean-Michel
dc.creatorGrinsztejn, Beatriz
dc.creatorTowner, William
dc.creatorHaubrich, Richard
dc.creatorNijs, Steven
dc.creatorVingerhoets, Johan
dc.creatorWoodfall, Brian
dc.creatorWitek, James
dc.date.accessioned2018-11-22T18:38:06Z
dc.date.accessioned2023-09-05T15:44:25Z
dc.date.available2018-11-22T18:38:06Z
dc.date.available2023-09-05T15:44:25Z
dc.date.created2018-11-22T18:38:06Z
dc.date.issued2010
dc.identifierKATLAMA, Christine. et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antiviral Therapy, v. 15, n. 7, p. 1045-1052, 2010.
dc.identifier1359-6535
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/30173
dc.identifier10.3851/IMP1662
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8669958
dc.languageeng
dc.rightsrestricted access
dc.titleEfficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials
dc.typeArticle


Este ítem pertenece a la siguiente institución